Skip to main content
Top
Published in: Pathology & Oncology Research 2/2012

01-04-2012 | Research

Targeting MET by Tyrosine Kinase Inhibitor Suppresses Growth and Invasion of Nasopharyngeal Carcinoma Cell Lines

Authors: Patrick C. Lau, Elaine Y. Wong

Published in: Pathology & Oncology Research | Issue 2/2012

Login to get access

Abstract

Nasopharyngeal carcinoma (NPC) represents a common cancer in endemic areas with high invasive and metastatic potential. It is now known that the HGF-MET signaling pathway plays an important role in mediating the invasive growth of many different types of cancer, including head and neck squamous cell carcinoma. HGF has been shown to stimulate NPC cell growth and invasion in cell line model. The current study aims at demonstrating the effect of MET inhibition by small molecule tyrosine kinase inhibitor PHA665752 on the growth and invasive potential of NPC cell lines. NPC cell lines were used for immunohistochemistry for the MET protein, as well as western blot analysis on MET together with its downstream cascade signaling proteins after treatment with PHA665752. The effect on cell growth, migration and invasion after PHA665752 treatment was also studied. MET inhibition by PHA665752 resulted in highly significant inhibition on NPC cell growth, migration and invasion in vitro. Down-regulation of phospho-MET, phospho-Akt, phospho-MAPK, phospho-STAT3, cyclin D1, β-catenin and PCNA was detected in NPC cells after PHA665752 treatment. MET inhibition with tyrosine kinase inhibitor resulted in suppression of NPC cell growth and invasive potential via down-regulation of a variety of signaling onco-proteins. MET is an important therapeutic target for NPC that warrants further studies and clinical trials.
Literature
1.
go back to reference Zur Hausen H, Schulte-Holthausen H, Klein G et al (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056–8PubMedCrossRef Zur Hausen H, Schulte-Holthausen H, Klein G et al (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056–8PubMedCrossRef
2.
go back to reference Tao Q, Chan ATC (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9:1–24PubMedCrossRef Tao Q, Chan ATC (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9:1–24PubMedCrossRef
3.
go back to reference Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef
4.
go back to reference Kam MKM, Teo PML, Chau RMC et al (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 60:1440–50PubMedCrossRef Kam MKM, Teo PML, Chau RMC et al (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 60:1440–50PubMedCrossRef
5.
go back to reference Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedCrossRef Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedCrossRef
6.
go back to reference Jeffers M, Rong S, Vande Woude GF (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505–13PubMedCrossRef Jeffers M, Rong S, Vande Woude GF (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505–13PubMedCrossRef
7.
go back to reference Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Bio 4:915–25CrossRef Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Bio 4:915–25CrossRef
8.
go back to reference Lau PC, Chan AT (2011) Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs 22:665–73PubMedCrossRef Lau PC, Chan AT (2011) Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs 22:665–73PubMedCrossRef
9.
go back to reference Horikawa T, Sheen T, Takeshita H et al (2001) Induction of c-Met proto-oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159:27–33PubMedCrossRef Horikawa T, Sheen T, Takeshita H et al (2001) Induction of c-Met proto-oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159:27–33PubMedCrossRef
10.
go back to reference Qian CN, Guo X, Cao B et al (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–96PubMed Qian CN, Guo X, Cao B et al (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–96PubMed
11.
go back to reference Zhou HY, Wan KF, Ip CK et al (2008) Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 582:3415–22PubMedCrossRef Zhou HY, Wan KF, Ip CK et al (2008) Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 582:3415–22PubMedCrossRef
12.
go back to reference Xie LQ, Bian LJ, Li Z et al (2010) Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol 17:1927–36PubMedCrossRef Xie LQ, Bian LJ, Li Z et al (2010) Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol 17:1927–36PubMedCrossRef
13.
go back to reference Glaser R, Zhang HY, Yao KT et al (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86:9524–8PubMedCrossRef Glaser R, Zhang HY, Yao KT et al (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86:9524–8PubMedCrossRef
14.
go back to reference Lo AK, Lo KW, Tsao SW et al (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173–80PubMedCrossRef Lo AK, Lo KW, Tsao SW et al (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173–80PubMedCrossRef
15.
go back to reference Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–9PubMedCrossRef Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–9PubMedCrossRef
Metadata
Title
Targeting MET by Tyrosine Kinase Inhibitor Suppresses Growth and Invasion of Nasopharyngeal Carcinoma Cell Lines
Authors
Patrick C. Lau
Elaine Y. Wong
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9452-1

Other articles of this Issue 2/2012

Pathology & Oncology Research 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine